Our Pipeline
IMYX-3 First in Class Neutrophil Modifying Drug
| Program | Discovery | Target Validation | In Vivo POC | Lead Selection | GLP Studies | CMC | IND |
|---|---|---|---|---|---|---|---|
|
IMYX-3 IBD
|
|
|
|
|
|
|
Q2 2027 |
|
IMYX-3 COPD
|
|
|
|
|
|
|
|
